Whitehawk director receives 38,040 stock options

Whitehawk Therapeutics director Mohammad Hirmand received a new stock option grant covering 38,040 shares of common stock.

Rhea-AI Filing Summary

Whitehawk Therapeutics director Mohammad Hirmand received a new stock option grant covering 38,040 shares of common stock. The option has an exercise price of $4.16 per share and expires on June 12, 2036.

All 38,040 option shares will vest 100% on the earlier of the one-year anniversary of the grant date or the day immediately before the next annual stockholder meeting, as long as he continues as a service provider. Following this grant, he holds 38,040 stock options directly from this award.

Insider Trade Summary

Grant/Award: 38,040 shares

Grant/Award 1 txn

Insider Hirmand Mohammad

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	38,040	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 38,040 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

Key Figures

Option grant size: 38,040 options Exercise price: $4.16 per share Expiration date: June 12, 2036 +3 more

6 metrics

Option grant size 38,040 options Stock Option (right to buy) granted on June 12, 2026

Exercise price $4.16 per share Conversion or exercise price of stock options

Expiration date June 12, 2036 Option term end for this grant

Post-grant options held 38,040 options Total derivative securities following the reported transaction

Vesting percentage 100% cliff vesting All shares vest in a single tranche once conditions are met

Vesting timing 1-year or pre-annual meeting Earlier of one-year anniversary or day before next annual stockholder meeting

Key Terms

Stock Option (right to buy), 2021 Equity Incentive Plan, Service Provider, vesting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

2021 Equity Incentive Plan financial

"as defined in the Issuer's 2021 Equity Incentive Plan"

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

vesting financial

"one hundred percent (100%) of the shares subject to the option shall vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the day immediately prior to the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Whitehawk Therapeutics (WHWK) director Mohammad Hirmand report on this Form 4?

Mohammad Hirmand reported receiving a grant of stock options for 38,040 shares of Whitehawk Therapeutics common stock. The options were awarded as compensation and are exercisable at an exercise price of $4.16 per share, subject to time-based vesting conditions.

What are the key terms of Mohammad Hirmand’s new WHWK stock options?

The grant covers 38,040 shares of common stock with a $4.16 exercise price and an expiration date of June 12, 2036. These options represent the right, but not the obligation, to buy WHWK shares at that fixed price once vested.

How do the vesting conditions work for the WHWK options granted to Mohammad Hirmand?

One hundred percent of the 38,040 option shares vest on the earlier of the one-year anniversary of the grant date or the day immediately before the next annual stockholder meeting. Vesting requires that he continue as a service provider under the 2021 Equity Incentive Plan.

Did Mohammad Hirmand buy or sell any Whitehawk Therapeutics shares in this filing?

No open-market buy or sell occurred; this filing reports a compensation-related stock option grant. The transaction is coded as an acquisition (A) of derivative securities, reflecting a new award rather than a market trade in WHWK common stock.

How many Whitehawk Therapeutics options does Mohammad Hirmand hold after this grant?

Following this Form 4 transaction, Hirmand holds 38,040 stock options from this reported award. These options are held directly and are tied to Whitehawk Therapeutics common stock, exercisable at $4.16 per share once fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hirmand Mohammad

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.16	06/12/2026		A		38,040		(1)	06/12/2036	Common Stock	38,040	$0	38,040	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

	/s/ Stephen Rodin, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)